Truist lowered the firm’s price target on Sage Therapeutics (SAGE) to $18 from $22, while keeping a Hold rating on the share. The firm notes Zurzuvae launch is off to a promising start, but upside is capped given 50/50 profit share with Biogen (BIIB). On the pipeline front, visibility is poor given competitive dynamics in essential tremor and Huntington’s for SAGE-324 and dalzanemdor, respectively. Also, recent failure of dalzanemdor in Parkinson’s does not bode well for upcoming data read-outs in Huntington’s and Alzheimer’s disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
- Sage Therapeutics price target lowered to $19 from $34 at Scotiabank
- Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer
- H.C. Wainwright concerned over Sage’s next readouts after SAGE-718 miss
